Teva Pharmaceutical Industries Limited (TEVA.TA)
- Previous Close
4,978.00 - Open
4,911.00 - Bid --
- Ask --
- Day's Range
4,807.00 - 4,915.00 - 52 Week Range
2,637.00 - 5,379.00 - Volume
1,345,230 - Avg. Volume
1,445,297 - Market Cap (intraday)
54.707B - Beta (5Y Monthly) 1.06
- PE Ratio (TTM)
-- - EPS (TTM)
-1.88 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 28, 2017
- 1y Target Est
14.86
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
www.tevapharm.com35,001
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: TEVA.TA
Performance Overview: TEVA.TA
Trailing total returns as of 4/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TEVA.TA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TEVA.TA
Valuation Measures
Market Cap
54.71B
Enterprise Value
118.36B
Trailing P/E
--
Forward P/E
5.40
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.91
Price/Book (mrq)
1.94
Enterprise Value/Revenue
7.47
Enterprise Value/EBITDA
75.97
Financial Highlights
Profitability and Income Statement
Profit Margin
-3.53%
Return on Assets (ttm)
4.54%
Return on Equity (ttm)
-7.36%
Revenue (ttm)
15.85B
Net Income Avi to Common (ttm)
-559M
Diluted EPS (ttm)
-1.88
Balance Sheet and Cash Flow
Total Cash (mrq)
3.23B
Total Debt/Equity (mrq)
249.48%
Levered Free Cash Flow (ttm)
3.29B
Research Analysis: TEVA.TA
Company Insights: TEVA.TA
TEVA.TA does not have Company Insights